Skip to Content

Provectus Lead Investigator Professor John F. Thompson to Present at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting on November 19, 2008

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its Phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Clinical Oncological Society of Australia (COSA) 2008 Annual Scientific Meeting (ASM) in Sydney, Australia. Professor Thompson's presentation, entitled "Chemoablation of Cutaneous and Subcutaneous Metastatic Melanoma Using PV-10," is scheduled for the afternoon of November 19th. One of the main focuses of the COSA meeting this year is melanoma.

Craig Dees, PhD, CEO of Provectus, said, "Our Company is actively engaged in opening a new front in the war on cancer, and the clinical study led by Professor Thompson is a major component of that effort. We look forward to Professor Thompson’s update on testing of PV-10 against melanoma."

Dees added, “We expect to have interesting information to announce later this week based on Professor Thompson’s presentation.”

Provectus began phase 2 testing of PV-10 in late 2007, aiming to assess PV-10 chemoablation in 80 subjects with Stage III or IV metastatic melanoma. The study is being conducted at centers in Sydney, Brisbane and Adelaide, Australia, and at the M.D. Anderson Cancer Center in Houston, TX, St. Luke’s Hospital & Health Network, in Bethlehem, PA, and the California Pacific Medical Center, in San Francisco, CA. Provectus expects to add additional sites in the U.S. and Australia in the near future.

According to the American Cancer Society, more than 62,000 people are expected to be diagnosed in the in the US in 2008 with melanoma, the most serious form of skin cancer, leading over 8,000 deaths this year.

For further details about COSA ASM 2008 visit:

About Provectus Pharmaceuticals, Inc. (

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP – Investor Relations
Bill Gordon, SVP – Media Relations


Posted: November 2008